Advertisement

Supply Chain



Shire's experimental drug to treat attention-deficit hyperactive disorder showed positive results in a recent study, bringing the company one step closer to earning approval from the Food and Drug Administration.

Orig3n, a Boston-based biotech company, is partnering with the San Francisco 49ers to reward football fans who support the company's human genome research.

Advertisement

Most Read

Advertisement
Advertisement